Publications
Detailed Information
Phase 2 Study of Everolimus Monotherapy in Patients With Nonfunctioning Neuroendocrine Tumors or Pheochromocytomas/Paragangliomas
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Kim, Tae-Won | - |
dc.contributor.author | Park, Young Suk | - |
dc.contributor.author | Shin, Sang Joon | - |
dc.contributor.author | Shin, Seong Hoon | - |
dc.contributor.author | Song, Eun-Kee | - |
dc.contributor.author | Lee, Hyo Jin | - |
dc.contributor.author | Lee, Kewn-Wook | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2021-01-31T11:05:10Z | - |
dc.date.available | 2021-01-31T11:05:10Z | - |
dc.date.created | 2020-12-16 | - |
dc.date.issued | 2012-12 | - |
dc.identifier.citation | Cancer, Vol.118 No.24, pp.6162-6170 | - |
dc.identifier.issn | 0008-543X | - |
dc.identifier.other | 119217 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173013 | - |
dc.description.abstract | BACKGROUND: The current study was conducted to evaluate the efficacy and safety of everolimus in the treatment of patients with nonfunctioning neuroendocrine tumors (NETs) or pheochromocytomas/paragangliomas. METHODS: Patients with histologically confirmed nonfunctioning NETs or pheochromocytomas/paragangliomas and with documented disease progression before study enrollment were eligible for the current study. Everolimus was administered daily at a dose of 10 mg for 4 weeks. Response was assessed by Response Evaluation Criteria In Solid Tumors (RECIST; version 1.0) every 8 weeks. The primary endpoint was the 4-month progression-free survival rate (PFSR). The hypothesis of the current study was that the 4-month PFSR would increase from 50% to 65%. Safety was evaluated using the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 3.0). RESULTS: A total of 34 patients were enrolled. Of these, 27 patients had nonfunctioning NETs, 5 had pheochromocytomas, and 2 had paragangliomas. The 4-month PFSR was 78%. Partial response (PR) was observed in 3 patients. Twenty-eight patients had stable disease (SD) and 2 patients developed progressive disease (PD). The response rate (RR) and overall disease control rate (DCR) were 9.0% (95% confidence interval [95% CI], 0%-18.6%) and 93.9% (95% CI, 85.8%-100%), respectively. The PFS was 15.3 months (95% CI, 4.6 months-26.0 months). Of the patients with nonfunctioning NETs, 3 achieved a PR and 23 had SD (RR, 11.1%; DCR, 100%); the PFS was 17.1 months (95% CI, 11.1 months-23.0 months) and the 4-month PFSR was 90.0%. Twenty-one patients (80.8%) demonstrated tumor shrinkage. In 7 patients with pheochromocytomas/paragangliomas, 5 achieved SD, and 2 developed PD. The PFS was 3.8 months (95% CI, 0.5 months-7.0 months) and the 4-month PFSR was 42.9%. Four patients demonstrated tumor shrinkage. The major grade 3/4 adverse events were thrombocytopenia (14.7%), hyperglycemia (5.9%), stomatitis (5.9%), and anemia (5.9%). CONCLUSIONS: Everolimus was associated with high therapeutic efficacy and tolerability in patients with nonfunctioning NETs, and demonstrated modest efficacy in patients with pheochromocytomas/paragangliomas. Cancer 2012;118:6162-70. (C) 2012 American Cancer Society. | - |
dc.language | 영어 | - |
dc.publisher | John Wiley & Sons Inc. | - |
dc.title | Phase 2 Study of Everolimus Monotherapy in Patients With Nonfunctioning Neuroendocrine Tumors or Pheochromocytomas/Paragangliomas | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1002/cncr.27675 | - |
dc.citation.journaltitle | Cancer | - |
dc.identifier.wosid | 000311911600021 | - |
dc.identifier.scopusid | 2-s2.0-84870679939 | - |
dc.citation.endpage | 6170 | - |
dc.citation.number | 24 | - |
dc.citation.startpage | 6162 | - |
dc.citation.volume | 118 | - |
dc.identifier.sci | 000311911600021 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | POSITRON-EMISSION-TOMOGRAPHY | - |
dc.subject.keywordPlus | MALIGNANT PHEOCHROMOCYTOMA | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | SUNITINIB | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | MTOR | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordPlus | THERAPIES | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | everolimus | - |
dc.subject.keywordAuthor | neuroendocrine tumor | - |
dc.subject.keywordAuthor | carcinoid | - |
dc.subject.keywordAuthor | pheochromocytoma | - |
dc.subject.keywordAuthor | paraganglioma | - |
dc.subject.keywordAuthor | positron emission tomography | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.